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Abstract
There is renewed interest in hepatitis A virus (HAV) pathogenesis and immunity after 2–3 decades 
of limited progress. From a public health perspective, the average age at infection has increased in 
developing countries, resulting in more severe hepatitis that is poorly understood mechanistically. 
More fundamentally, there is interest in comparing immunity to HAV and hepatitis C virus 
(HCV): small, positive-strand RNA viruses with very different infection outcomes. Here, we 
review evidence that circulating HAV virions are cloaked in membranes, with consequences for 
induction of innate immunity and antibody-mediated neutralization. We also consider the 
contribution of CD4+ helper versus CD8+ cytotoxic T cells to antiviral immunity and liver injury, 
and present a model of non-cytotoxic immune control of HAV infection.
Introduction
Hepatitis A virus (HAV) is a positive-strand RNA virus classified in the family 
Picornaviridae. A prominent cause of fecal-orally transmitted acute viral hepatitis (Figure 1) 
and prevalent where sanitation is poor, it was first visualized in 1973 by immune electron 
microscopy in the feces of human volunteers [1]. Only a single HAV serotype exists, and it 
has never been shown to establish longterm persistent infections. Interest in HAV peaked in 
the late 1980s, but then declined with introduction of successful formalin-inactivated 
vaccines and the discovery of hepatitis C virus (HCV). HCV, also a positive-strand RNA 
virus (family Flaviviridae), has a striking capacity to establish persistence and strong 
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association with chronic hepatitis, progressive hepatic fibrosis and liver cancer – clinical 
outcomes never linked to HAV. However, recent years have marked a resurgence of interest 
in HAV, sparked in part by the desire to understand these different infection outcomes. 
Many potential explanations have been advanced [2], but the mechanisms underlying HCV 
persistence remain elusive. Contrasts in the host response to HAV and HCV that are now 
emerging may provide important clues to this mystery. Recent studies have brought to light 
several unexpected aspects of the innate and adaptive immune response to HAV, and 
revealed paradigm-breaking features of HAV structure and the HAV lifecycle. Here, we 
review these recent developments and outline the questions they pose for future 
investigations.
Structure of the infectious HAV particle
While the organization of the HAV genome resembles other picornaviruses (Figure 2), 
recent crystallographic studies show the capsid to be intermediate in structure between that 
of ‘primitive’ insect dicistroviruses and mammalian picornaviruses such as poliovirus [3]. 
Although it was recognized that the HAV structure must differ from other picornaviruses 
given its impressive physical stability and a distinct morphogenesis pathway [4,5], the 
degree of difference comes as a surprise and indicates that HAV diverged from other 
picornaviruses eons ago. The capsid is also generally devoid of the surface topology that 
provides binding sites for cellular receptors on other picornaviruses [3], raising questions as 
to how HAV enters cells.
Even more surprising is the discovery that HAV is released from infected hepatocytes 
cloaked in host membranes and thereby hidden from neutralizing antibodies [6]. These 
membrane-wrapped virions (‘eHAV’) (Figure 2) are infectious and possess key attributes of 
conventional enveloped viruses, including loss of infectivity upon extraction with organic 
solvents. The membrane cloaking the virus is not decorated with virally-encoded 
glycoproteins, however, providing an important distinction and leading us to consider these 
eHAV virions to be “quasi-enveloped” [7]. While the largest of the 4 capsid proteins, VP1, 
is 274 amino acid residues in length in ‘naked’, non-enveloped HAV virions, it has an 8 kDa 
carboxyterminal extension (pX, also known as 2A) and is approximately 71 residues longer 
in eHAV (VP1-pX) [6]. pX is unrelated to any other known protein. It plays a critical role in 
capsid assembly and likely eHAV envelopment, but is cleaved from the capsid upon loss of 
the membrane [5,6].
The biogenesis of quasi-enveloped eHAV particles is dependent upon ALIX and VPS4B [6], 
components of the cellular endosomal sorting complex required for transport (ESCRT) 
commonly involved in budding of conventional enveloped viruses [8]. ALIX appears to bind 
tandem YPX3L ‘late domains’ in VP2 [6]. Although confirmatory ultrastructural data are 
lacking, this likely promotes the budding of assembled capsids into multivesicular bodies 
(MVBs), leading to eHAV envelopment and a release mechanism resembling exosome 
biogenesis [9]. Since the VP2 late domains are buried beneath the surface of the naked 
capsid in the X-ray structure [3], the capsid appears to undergo significant conformational 
rearrangement upon membrane dissolution and loss of pX.
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Only quasi-enveloped eHAV is detected in serum and plasma during acute infection, 
whereas non-enveloped virions are shed in feces [6]. While not well understood, these naked 
virions are probably produced in the liver and secreted in bile. They may be released from 
hepatocytes as eHAV, but converted to naked virions in the proximal biliary canaliculus 
where local bile salt concentrations could be sufficient to dissolve the membrane [10]. 
However, available data do not exclude an intestinal source [11]. The non-enveloped virion 
is remarkably stable to heat, low pH, and drying, facilitating viral transmission [3,4]. This 
dual lifestyle, quasi-enveloped and cloaked from neutralizing antibodies within the host 
while devoid of membranes and stable in the environment, provides unique opportunities for 
spread within and between hosts.
Cellular entry of eHAV occurs via a chloroquine-sensitive endocytic pathway distinct from 
entry of non-enveloped virions [6]. Entry of both virion types is dependent upon the 
phosphatidylserine receptor, T cell immunoglobulin and mucin domain-1 (TIM-1, also 
referred to as HAVCR1), but little else is known about this. Important questions that remain 
unresolved is how the eHAV membrane alters cellular tropism, and whether a distinct 
receptor is involved in eHAV entry.
Innate and cell-intrinsic immune responses
Type 1 interferon (IFN-α/β) is both a first line of defense against viruses and important in 
optimal priming of subsequent adaptive cellular immunity. HAV evokes a minimal 
intrahepatic type I IFN response in chimpanzees, far less quantitatively than that observed in 
acute HCV infections (Figure 3) [12]. Despite this, intrahepatic viral RNA is 100- to 1000-
fold more abundant in acute HAV versus HCV infection. There are several possible 
explanations for these differences. Both viruses express proteases that cleave MAVS and 
TRIF, key adaptor proteins in RIG-I-like receptor (RLR) and Toll-like receptor 3 (TLR3) 
signaling, respectively. This represents an interesting example of convergent evolution, as 
the responsible HAV proteases, 3ABC and 3CD [13,14], are structurally and 
phylogenetically unrelated to the HCV protease, NS3/4A [15]. However, the mature HAV 
protease, 3Cpro, also cleaves NEMO, a bridging adaptor required for NF-κB activation and 
IFN-β expression [16]. The targeting of NEMO by HAV may provide an additional level of 
disruption in interferon signaling beyond that imposed by HCV, possibly contributing to less 
interferon-stimulated gene (ISG) expression in hepatitis A.
Differences may also exist in the plasmacytoid dendritic cell (pDC) response to these 
infections. pDCs are activated and produce IFN through a TLR7 pathway when placed in 
co-culture with HCV-infected cells [17]. Although they do not sense some picornaviruses 
unless the virus is complexed with antibodies [18,19], they do produce substantial amounts 
of IFN-α when co-cultured with HAV-infected cells [20]. pDCs preferentially take up quasi-
enveloped eHAV virions, which stimulate IFN production in the absence of genome 
replication. pDCs sense HCV RNA carried as cargo from infected cells by exosomes [21], a 
mechanistically similar process since eHAV resemble exosomes and may share a similar 
biogenesis. A key difference between HAV and HCV, however, may be in how pDCs are 
recruited to the liver. In chimpanzees, numerous pDCs are present within the liver by the 
end of the first week of HAV infection (Figure 1) [20]. For unknown reasons, they disappear 
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and cannot be detected at the peak of virus replication and acute inflammation 2–3 weeks 
later. Less is known about temporal aspects of the pDC response in HCV infection, but 
pDCs appear to be abundant in chronically infected livers where ISG expression is often 
strong [22].
HCV may also replicate less efficiently than HAV, resulting in lower expression of HCV 
proteins and therefore less efficient antagonism of IFN signaling. HCV is exquisitely and 
uniquely sensitive to oxidative membrane damage, whereas HAV is not [23]. Because HCV 
infection induces oxidative stress, an auto-regulatory circuit unique to HCV may ensure that 
replication is maintained at low levels within the liver.
Adaptive Immunity and Control of HAV Infection.
HAV-specific humoral and cellular immune responses typically appear 4–5 weeks after 
infection with the onset of hepatitis (Figure 1). Increased numbers of plasmablasts secreting 
IgM with a variety of specificities are present at this point in time [24], but this rapidly 
transitions to a neutralizing IgG response that provides life-long protection from hepatitis A 
[25]. Passive transfer of anti-HAV antibodies or vaccination up to two weeks after exposure 
to the virus can prevent liver disease [26], indicating that antibodies also have the potential 
to modulate the course of an established infection. Neutralizing antibodies recognize a small 
number of closely-positioned epitopes in the highly conserved VP1, VP3 [27] and possibly 
VP2 [3] capsid proteins.
Non-enveloped HAV are readily neutralized when pre-treated with antibodies before 
inoculation onto cultured cells [28], and thus it has been assumed that immunization or 
immune globulins protect against disease by neutralizing circulating virus. However, quasi-
enveloped eHAV virions (the only virion type found in blood) are completely resistant to 
neutralization in classical infectious focus-reduction assays since the membrane effectively 
cloaks the capsid [6]. Despite this, replication is inhibited when anti-capsid antibodies are 
added to cells several hours after eHAV infection [6]. Neutralization probably occurs within 
late endosomes or lysosomes, where the membrane is likely to be removed and the capsid 
exposed during entry of the virus. The kinetics of such post-endocytic neutralization suggest 
that eHAV entry is relatively slow, requiring 4–6 hours for dissolution of the membrane. In 
contrast, antibodies have no effect when added even immediately after infection of cells 
with non-enveloped HAV [6].
HAV-specific cytotoxic CD8+ T cell responses were first described in the blood [29] and 
liver [30] of jaundiced patients with acute hepatitis A 25 years ago. Since the icteric phase of 
infection typically coincides with a sharp decline in viremia, this CD8+ T cell response was 
correlated kinetically with control of virus replication (Figure 1). The detection of cytotoxic 
CD8+ T cells during this acute phase of the infection was also consistent with liver injury 
being immune mediated, since robust virus replication occurs during the preceding 2–3 
week prodromal period without liver disease. However, a series of recent studies have 
provided fresh insight into cellular immune responses using newer methods for more precise 
measurement of T cell frequency and function. Epitopes presented by defined class I 
epitopes were mapped in human subjects infected during a recent hepatitis A outbreak [31]. 
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Whereas CD8+ T cells targeting these epitopes were successfully expanded from blood of 
patients with acute HAV infection, most circulating CD8+ T cells were present at 
frequencies too low for direct visualization with class I tetramers. Effector functions were 
not assessed. A survey of CD4+ helper and CD8+ cytotoxic T cell activity was also 
undertaken in two chimpanzees with relatively mild transient hepatitis 3–4 weeks after 
experimental challenge [32]. In that study, CD8+ T cells were visualized in blood with class 
I tetramers, but they targeted few epitopes and did not gain effector functions until after 
viremia and hepatitis had substantially declined (Figure 1). On the other hand, multi-
functional HAV-specific CD4+ T cells targeting over 30 discrete class II epitopes appeared 
in blood at much higher frequency well before CD8+ T cells were detected. Control of 
viremia was more closely linked to expansion of functional CD4+ T cells than CD8+ T cells 
[32]. The frequency of HAV-specific CD4+ T cells declined very slowly in blood after 
termination of viremia and fecal shedding of virus. Slow contraction of CD4+ T cells 
paralleled gradual clearance of HAV RNA from the liver over 8–9 months [12,32]. While 
the continued presence of intrahepatic HAV RNA for such a long period of time was 
unexpected, it is consistent with a role for residual viral antigen in prolonging CD4+ but not 
CD8+ T cell contraction as described recently in lymphocytic choriomeningitis virus 
(LCMV)-infected mice [33].
While the detection of CD8+ T cells in patients with acute hepatitis A provided an early 
conceptual framework explaining both acute liver injury and immune control of HAV 
(Figure 4, left panel), liver injury can range from inapparent to severe (even fatal) in acute 
HAV infection. This suggests that cytotoxic CD8+ T cell activity is likely to be a variable 
feature in hepatitis A. More recent studies of patients infected during a recent nationwide 
epidemic of hepatitis A in South Korea established an inverse correlation between the 
frequency and function of regulatory T cells (Treg) in blood and the severity of liver injury 
as reflected by increases in in serum alanine aminotransferase (ALT) [34]. The frequency of 
circulating HAV-specific CD8+ T cells did not correlate with Treg activity [34], raising 
questions about the identity of effector cells that mediate immunopathology. Little is known 
about the role of NK and NKT cells in this infection. Moreover, the potential for HAV to 
modulate NKT cell cytotoxic activity [35] as well as Treg function [36] through direct 
interaction of the viral capsid with the TIM-1 receptor highlights the complexity of host 
virus-interactions in this infection.
Conclusion: Towards a more flexible model of HAV immunity and 
pathogenesis
The new findings summarized above demand a rethinking of the relationships between 
innate and adaptive immune responses and acute liver injury, as well as immune elimination 
of HAV. A new model might place less emphasis on cytotoxic elimination of HAV-infected 
hepatocytes by CD8+ T cells, particularly if the delay in acquisition of effector function 
observed in chimpanzees [32] is recapitulated in future studies of human subjects (Figure 4, 
right panel). A defect in early antiviral effector function by CD8+ T cells is probably not 
caused by an absence of help because CD4+ T cells in the HAV-infected chimpanzees 
produced IL-2, IL-21, and IFN-γ [32]. Interference with class I antigen processing and 
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presentation has been described for other picornaviruses [37], but the relevance of this to 
generation of CD8+ T cell immunity in HAV infection remains to be determined. Weak type 
I IFN responses in the liver [12] might also dampen CD8+ T cell immunity as this cytokine 
delivers an important differentiation signal in some virus infections. As discussed above, 
more needs to be learned about the fate of pDCs in the acutely infected liver in order to 
better understand the paucity of type I IFN responses and how it might limit development of 
CD8+ T cell responses.
The concept that CD4+ T cells provide direct control of virus infections through production 
of antiviral cytokines is gaining favor [38]. Non-cytotoxic control of virus replication by 
CD4+ T cells could be a general mechanism for terminating HAV infection regardless of 
CD8+ T cell activity. CD4+ T cells could also have a protective role in the post-
convalescent phase of infection, when HAV RNA genomes are gradually lost from liver. 
Clinical relapse associated with apparent recrudescent infection after the initial resolution of 
symptoms of hepatitis A [39], and prolonged presence of HAV RNA in serum of some 
adults [40], suggests the existence of a non-cytotoxic mechanism of immune surveillance 
that is effective in most infections. CD4+ T cells, that contract gradually after apparent 
resolution of infection [32], could serve this function. However, the persistence of viral 
RNA in the liver for months after the cessation of fecal shedding [12] remains to be 
explained. One interesting possibility is that virions may remain complexed to neutralizing 
antibodies within endolysosomes.
Finally, despite its major fecal-oral route of transmission, the role of the gut as a site for 
HAV replication and perhaps as a regulator of immune responses to the virus has received 
insufficient attention [41]. Early studies in owl monkeys suggest HAV may replicate in the 
lower gastrointestinal tract [11], but this has never been confirmed in humans. Local 
inflammatory signals elicited by even limited replication of HAV in the gut could 
substantially influence the nature of immunity and disease severity in liver [41].
A better understanding of HAV pathogenesis and immunity could provide general insight 
into mechanisms of immune evasion and control of other viruses that infect the liver, 
including HCV. A focus on human subjects who are infected as a result of sporadic and 
epidemic spread of the virus provides one path forward. However, there is a need for a 
renewed effort to better characterize non-human primate models of hepatitis A and perhaps 
even the adaptation of HAV to replication in rodents to facilitate access to tissue and 
experimental manipulation of immune responses.
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• Circulating virions are cloaked in membranes and resistant to neutralization
• Acute HAV infection induces a meager intrahepatic type I interferon response
• CD4+T cells appear earlier and acquire effector function before CD8+ T cells
• Immune control of HAV may be predominantly non-cytotoxic and cytokine 
driven
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Virologic and immunologic events during acute HAV infection in a chimpanzee inoculated 
intravenously with wild-type HAV [12,20,32]. Working from the bottom up, the lowest 
panel shows the presence of viral RNA (GE, genome equivalents) in serum (GE/ml), feces 
(GE/gm), and liver tissue (GE/µg total RNA) in relationship to serum alanine 
aminotransferase (ALT) activity shown in the shaded zone [12]. The prolonged persistence 
of intrahepatic HAV RNA is surprising. The panel immediately above shows total anti-HAV 
antibody (% blocking in a competitive ELISA assay) and IgM anti-HAV (ELISA O.D.) 
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[12]. The next two panels show frequencies of HAV-specific CD4+ and CD8+ T cells 
among peripheral blood mononuclear cells, as determined in an IFN-γ intracellular staining 
(ICS) assay [32]. CD8+ cells were also quantified on the basis of staining with tetramers 
targeting epitopes in pX, 2B, and 3Dpol (see Figure 2). Note the difference in scale between 
CD4+ and CD8+ T cell frequencies. The top panel shows type I IFN responses to HAV 
infection as reflected in minimal and only early serum IFN-α levels detectable by cytokine 
ELISA, and minimal increases in intrahepatic expression of IFN-stimulated genes: IFIT1 
and ISG15 [12]. pDCs were detected in liver tissue only at 1 week after viral challenge 
(arrow) [20]. (The authors gratefully acknowledge the essential involvement of Dr. Robert 
Lanford in these comprehensive chimpanzee studies.)
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Schematic showing organization of the 7.5 kb single-stranded, positive-sense RNA genome 
of HAV. The 2227 amino acid residue polyprotein is comprised of both structural and 
nonstructural proteins, and is flanked by 5. and 3. untranslated RNA segments containing 
regulatory elements. Below are shown electron microscopic images of gradient purified 
quasi-enveloped eHAV (panels i–iv) and naked, non-enveloped HAV (panel v) released 
from infected hepatoma cell cultures. (Reproduced with permission from Feng et al. Nature 
2013, 496:367–371).
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Comparison of maximum intrahepatic and serum viral RNA abundance and interferon-
stimulated gene (ISG15) expression in acute, resolving HAV (n = 3) and HCV (n = 8) 
infections in experimentally infected chimpanzees. Differences in intrahepatic genome copy 
numbers (p=0.01) and ISG expression (p=0.01) were significant by two-sided Mann-
Whitney test. Adapted from Lanford et al. [12].
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Proposed cellular interactions in the liver during acute hepatitis A. HAV infection of the 
liver is thought to be non-cytopathic, resulting in release of quasi-enveloped virions from the 
basolateral plasma membrane of hepatocytes into the circulation and apical release of virus 
into the biliary system resulting in fecal shedding of naked HAV virions [6]. Contact 
between infected hepatocytes and plasmacytoid dendritic cells (pDC) results in transfer of 
eHAV to pDCs and signaling for production of type I IFN [20], a cytokine important to 
development of adaptive cellular immune responses. Cytotoxic cells, including virus-
specific CD8+ T cells, NK cells, and NKT cells, have been implicated in acute 
hepatocellular injury during HAV infection. Liver damage can range from mild and 
inapparent, to severe and fatal, and may be regulated in part by the strength of the innate 
immune response, including type I IFN production by pDC. We propose that non-cytotoxic 
control of HAV replication is a central feature of infection and immune control of the virus 
regardless of disease severity. CD4+T helper cells are a potential source of antiviral 
cytokines because they appear in blood and acquire effector function earlier than CD8+ T 
cells [32], as shown in Figure 1. A primary site of virus replication within the gut after per-
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oral infection with the virus, or secondary to shedding of virus from the liver, remains 
speculative but could influence infection and immunity in the liver.
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